Funder: National Institutes of Health

Due Dates: June 17, 2025 (Letter of Intent) | July 17, 2025 (Application) | Oct 20, 2025 (LOI) | Nov 19, 2025 (Application) | Feb 24, 2026 (LOI) | Mar 26, 2026 (Application) | June 17, 2026 (LOI) | July 17, 2026 (Application) | Oct 20, 2026 (LOI) | Nov 19, 2026 (Application)

Funding Amounts: UG3: up to $500,000 direct costs/year (2 years); UH3: no set limit (up to 3 years); budgets must reflect project needs.

Summary: Supports phased development and testing of digital therapeutics for substance use disorders, aiming for FDA authorization and broad dissemination.

Key Information: Both pre-clinical and clinical projects are eligible; foreign and domestic organizations may apply; clinical trial is optional.